Page 26 - Lupin
Lupin spends big on quality control as US FDA ups scrutiny on Indian pharma
Employees are often videotaped to ensure they follow standard operating procedure
 "Lupin spends big on quality control as US FDA ups scrutiny on Indian pharma")
Lupin plans to consolidate generic products
Drug major Lupin is devising plans to consolidate its generic portfolio across key geographies, including the US, with a focus on expansion of complex and specialty products. The Mumbai-based company may look at acquisitions, besides enhanced investment in research and development (R&D), to achieve desired results. "Moving forward, we will consolidate on our generic portfolio while focusing on complex generics and speciality products," Lupin Vice-Chairman Kamal K Sharma said in his address to shareholders in the company's Annual Report for 2016-17. The drugmaker expects to tackle this challenge with appropriate acquisitions, calibrated investments in R&D, supported by right skill sets, he added. "This would enable us to enhance the quality of our business and transcend from the existing paradigm towards new horizons," Sharma said. Elaborating, Lupin MD Nilesh Gupta and CEO Vinita Gupta said the company will consolidate on the generic position across ...
 "Lupin plans to consolidate generic products")
Lupin's 4.5% rise pushes Nifty Pharma index up by 1.5%
Nifty Pharma gained over 1.5% today, making it the top performing index among other sectora
 "Lupin's 4.5% rise pushes Nifty Pharma index up by 1.5%")
Lupin rebounds 5% from 52-week low on drug launch
The stock up 4% to Rs 1,086, bouncing back 5% from 52-wk low of Rs 1,036 hit in intra-day trade
Dr Reddy's slips to 4th spot in sales revenue as Lupin, Aurobindo race past
Lupin wins second spot with 24% growth in consolidated revenues at Rs 17,494 cr
Centrum maintains buy rating on Lupin; sets target at Rs 1300
Lupin is the market leader in 45 of the 139 products in the US' generic market
 "Centrum maintains buy rating on Lupin; sets target at Rs 1300")
Weak US sales pull down Lupin show
Operating performance in the March quarter also impacted by one-offs
 "Weak US sales pull down Lupin show")
FY18 will be challenging for Lupin: Nilesh Gupta
Interview with Lupin managing director Nilesh Gupta
 "FY18 will be challenging for Lupin: Nilesh Gupta")
Lupin's Q4 net profit nearly halves to Rs 380 cr as US sales slump 13%
Manufacturing costs and other expenses rose about 30% in the quarter
 "Lupin's Q4 net profit nearly halves to Rs 380 cr as US sales slump 13%")
USFDA makes 8 observations after inspecting Lupin's Aurangabad facility
Inspection was completed on April 26
Lupin hits fresh 32-month low
Lupin dipped 3% to Rs 1,242, its fresh 32-month low on BSE in intra-day trade
Near-term concerns for Lupin
US regulator's observations add to US pressure
Lupin hits 32-month low; stock down 5% in two days
In past one-month, the stock declined 11.7% as compared to unchanged in Sensex.
 "Lupin hits 32-month low; stock down 5% in two days")
Lupin gets USFDA nod to sell generic hypertension drug in US
The Mumbai-based company's product is the generic version of Daiichi Sankyo Inc's Benicar tablets
Lupin hits fresh 52-week low; down 7.5% in six days
The stock hit a fresh 52-week low of Rs 1,320, down 1.3% on the BSE.
 "Lupin hits fresh 52-week low; down 7.5% in six days")
Lupin gets USFDA nod for drug
Wellbutrin tablets have sales of $755 million in the American market
Patent infringement: Lupin's arm to pay damages to Bayer
An Australian court has asked Generic Health to pay A$30 million to Bayer Pharmaceuticals
Lupin expects muted growth in the US despite new launches
About 25 products to be launched next year will only partly compensate price erosion
 "Lupin expects muted growth in the US despite new launches")
Lupin expects muted growth in the US despite new launches
Nilesh Gupta, managing director for Mumbai based pharma major Lupin is trying to reset investors expectation as its mojo in the US market is set to get weaker in the near term.The company that reported Rs 12,958 crore revenue in the nine months of current financial earns about 48% from the US markets. "With one of the strongest pending pipelines in the US at its disposal, the company is well poised to address the pricing issue," said Siddhant Khandekar, analyst with ICICI Securities in its recent report. "We expect US sales to grow at 18% CAGR in FY16-19E to Rs 9642 crore," the report said.Following the $880 million acquisition of Gavis in 2015, the company has stepped-up product launches and ramped-up specialty drugs offering to protect its revenue from the US market.It owns one of the strongest ANDA (Abbreviated New Drug Application) pipeline comprising 344 filed and 137 pending approvals including 44 FTFs (First to File). This acquisition has strengthened its position in ...
Our priority is to acquire speciality drugmakers in the US: Nilesh Gupta
Interview with the managing director of Lupin